Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth

Open access
Dewaele, Michael, Tabaglio, Tommaso, Willekens, Karen, Bezzi, Marco, Teo, Shun Xie, Low, Diana H.P., Koh, Cheryl M., Rambow, Florian, Fiers, Mark, Rogiers, Aljosja, Radaelli, Enrico, Al-Haddawi, Muthafar, Tan, Soo Yong, Hermans, Els, Amant, Frederic, Yan, Hualong, Lakshmanan, Manikandan, Koumar, Ratnacaram Chandrahas, Lim, Soon Thye, Derheimer, Frederick A., Campbell, Robert M., Bonday, Zahid, Tergaonkar, Vinay, Shackleton, Mark, Blattner, Christine, Marine, Jean-Christophe, Guccione, Ernesto · 2015 · Journal of Clinical Investigation

Abstract

MDM4 is a promising target for cancer therapy, as it is undetectable in most normal adult tissues but often upregulated in cancer cells to dampen p53 tumor-suppressor function. The mechanisms that underlie MDM4 upregulation in cancer cells are largely unknown. Here, we have shown that this key oncogenic event mainly depends on a specific alternative splicing switch. We determined that while a nonsense-mediated, decay-targeted isoform of MDM4 (MDM4-S) is produced in normal adult tissues as a result of exon 6 skipping, enhanced exon 6 inclusion leads to expression of full-length MDM4 in a large number of human cancers. Although this alternative splicing event is likely regulated by multiple splicing factors, we identified the SRSF3 oncoprotein as a key enhancer of exon 6 inclusion. In multiple human melanoma cell lines and in melanoma patient-derived xenograft (PDX) mouse models, antisense oligonucleotide-mediated (ASO-mediated) skipping of exon 6 decreased MDM4 abundance, inhibited melanoma growth, and enhanced sensitivity to MAPK-targeting therapeutics. Additionally, ASO-based MDM4 targeting reduced diffuse large B cell lymphoma PDX growth. As full-length MDM4 is enhanced in multiple human tumors, our data indicate that this strategy is applicable to a wide range of tumor types. We conclude that enhanced MDM4 exon 6 inclusion is a common oncogenic event and has potential as a clinically compatible therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci82534

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 173

Metadata

Authors
Dewaele, M., Tabaglio, T., Willekens, K., Bezzi, M., Teo, S. X., Low, D. H. P., Koh, C. M., Rambow, F., Fiers, M., Rogiers, A., Radaelli, E., Al-Haddawi, M., Tan, S. Y., Hermans, E., Amant, F., Yan, H., Lakshmanan, M., Koumar, R. C., Lim, S. T., Derheimer, F. A., Campbell, R. M., Bonday, Z., Tergaonkar, V., Shackleton, M., Blattner, C., Marine, J.-C., & Guccione, E.
Venue
Journal of Clinical Investigation
Published
2015-11-23
Volume
126
Issue
1
Pages
68-84
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2174441123
Cited by
173
References
15
FWCI
6.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth. https://app.cochat.ai/papers/10.1172/jci82534
The paper
Dewaele, M., Tabaglio, T., Willekens, K., Bezzi, M., Teo, S. X., Low, D. H. P., Koh, C. M., Rambow, F., Fiers, M., Rogiers, A., Radaelli, E., Al-Haddawi, M., Tan, S. Y., Hermans, E., Amant, F., Yan, H., Lakshmanan, M., Koumar, R. C., Lim, S. T., . . . Guccione, E. (2015). Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth. Journal of Clinical Investigation. https://doi.org/10.1172/jci82534

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.